🇺🇸 United States Country × Condition
multiple myeloma Clinical Trials in United States
Active clinical trials for multiple myeloma with research sites in United States. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 21 // Recruiting: 21 Phases: Phase 2, Phase 1, Phase 2 // Updated: Daily
Total Trials
21
Recruiting Now
21
Country
🇺🇸 United States
Active Trials in United States (21)
NCT05031897 Phase 2
Recruiting
Two Step Haplo With Radiation Conditioning
Enrollment
63 pts
Country
🇺🇸 United States
Thomas Jefferson University
View Trial → NCT03761108 Phase 1, Phase 2
Recruiting
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Enrollment
387 pts
Country
🇺🇸 United States
Regeneron Pharmaceuticals
View Trial → NCT06953960 Phase 1, Phase 2
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Enrollment
130 pts
Country
🇺🇸 United States
AbbVie
View Trial → NCT03689595
Recruiting
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Enrollment
30,000 pts
Country
🇺🇸 United States
Dana-Farber Cancer Institute
View Trial → NCT05336383 Phase 2
Recruiting
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
Enrollment
30 pts
Country
🇺🇸 United States
M.D. Anderson Cancer Center
View Trial → NCT06997081 Phase 2
Recruiting
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
Enrollment
104 pts
Country
🇺🇸 United States
University of Miami
View Trial → NCT06572605 Phase 1, Phase 2
Recruiting
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
Enrollment
20 pts
Country
🇺🇸 United States
City of Hope Medical Center
View Trial → NCT05243797 Phase 3
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Enrollment
1,594 pts
Country
🇺🇸 United States
European Myeloma Network B.V.
View Trial → NCT06348108 Phase 1
Recruiting
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Enrollment
32 pts
Country
🇺🇸 United States
Alfred Chung, MD
View Trial → NCT06711705 Phase 2
Recruiting
Elranatamab in Relapsed/Refractory Multiple Myeloma
Enrollment
33 pts
Country
🇺🇸 United States
University of California, San Diego
View Trial → NCT01676805
Recruiting
Tissue Collection for Studies of Lymph Cancer
Enrollment
1,295 pts
Country
🇺🇸 United States
National Cancer Institute (NCI)
View Trial → NCT06138275 Phase 2
Recruiting
Elranatamab in R/R Multiple Myeloma
Enrollment
32 pts
Country
🇺🇸 United States
Massachusetts General Hospital
View Trial → NCT07258511 Phase 3
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Enrollment
400 pts
Country
🇺🇸 United States
Janssen Research & Development, LLC
View Trial → NCT06483100 Phase 2
Recruiting
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Enrollment
65 pts
Country
🇺🇸 United States
Washington University School of Med...
View Trial → NCT06066346 Phase 2
Recruiting
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Enrollment
17 pts
Country
🇺🇸 United States
Memorial Sloan Kettering Cancer Cen...
View Trial → NCT06152575 Phase 3
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Enrollment
492 pts
Country
🇺🇸 United States
Pfizer
View Trial → NCT05956457
Recruiting
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Enrollment
100 pts
Country
🇺🇸 United States
Pack Health
View Trial → NCT07105059 Phase 1
Recruiting
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Enrollment
18 pts
Country
🇺🇸 United States
Memorial Sloan Kettering Cancer Cen...
View Trial → NCT06588413 Phase 3
Recruiting
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Enrollment
172 pts
Country
🇺🇸 United States
Augusta University
View Trial → NCT06340646
Recruiting
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Enrollment
990 pts
Country
🇺🇸 United States
Washington University School of Med...
View Trial → NCT06142396 EARLY_Phase 1
Recruiting
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Enrollment
30 pts
Country
🇺🇸 United States
Augusta University
View Trial → Frequently Asked Questions
How many multiple myeloma clinical trials are active in United States?
There are currently 21 active clinical trials for multiple myeloma with sites in United States, of which 21 are actively recruiting patients.
How can I join a multiple myeloma clinical trial in United States?
To join a multiple myeloma clinical trial in United States, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in United States directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are multiple myeloma trials in United States?
Active multiple myeloma trials in United States span Phase 2, Phase 1, Phase 2, Phase 3, Phase 1, EARLY_Phase 1. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.